This phase 2, open-label, interventional study examined the safety and efficacy of pembrolizumab for patients with advanced, metastatic esophageal carcinoma that has progressed after 2 or more lines of systemic therapy.
https://ift.tt/2ScIHM9
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου